

100 Majestic	Way, Bange	or, PA	18013 /	www.biospectra.us
		7		

Effective Date: 12-JUL-2023	12-JUL-2026	: Date of Next Review
Prepared By: Amy Yencho	BSI-COA-0196 v.1.1	: Supersedes
QA/QC Approval: Wayne Talamonti	Dora Meissner	: Management Approval
Reason for Revision: See Revision History in MasterControl.		

## CERTIFICATE OF ANALYSIS URIDINE

## **BIO EXCIPIENT GRADE / URID-3250-92**

LOT: URID-0124-00014

 $C_9H_{12}N_2O_6$  \(^+\) F.W. 244.20 g/mol \(^+\) CAS# 58-96-8 Manufacture Date: 06/12/23 Retest Date: 06/30/25 Manufacturing Site: 100 Majestic Way, Bangor PA, 18013

Packaging Date: 07/19/24

Packaging Site: 100 Majestic Way, Bangor PA, 18013

ANALYSIS		SPECIFICATION	TEST RESULT
Appearance and Color		White to almost white powder	White to almost white powder
Assay (HPLC)		98.0 - 102.0%	100.5%
Bioburden	TAMC TYMC	$\leq 100$ CFU/g $\leq 100$ CFU/g	<100CFU/g <100CFU/g
Endotoxin		≤ 0.5 EU/mg	<0.5EU/mg
Heavy Metals		≤ 10 ppm	<10 ppm
HPLC Purity		≥ 99%	100%
Identification (IR)		Conforms to Spectrum of Reference Standard	Conforms to Spectrum of Reference Standard
Loss on Drying		≤ 0.5%	0.1 %
Residue on Ignition		≤ 0.1%	<0.1 %
Transparency		$\geq 98.0\%$	99.9%
UV Assay		≥ 98.0%	98.8%

COUNTRY OF ORIGIN: U.S.A.

TEST METHOD REFERENCE: DCN: BSI-ATM-0086

<u>INTENDED USE:</u> Material represented by this Certificate of Analysis is suitable for use as an Excipient. It is manufactured in accordance with the ICH Q7 Good Manufacturing Practice Guide. The material represented by this Certificate of Analysis is not suitable to be used as an Active Pharmaceutical Ingredient, Drug Product, or Household Item.

Prepared by: Sluff Hull	Date: 7 23 24 Job Title: QA TECH TI
Reviewed by: Jan Bugh	Date: 7/23/2Y Job Title: Of Supervisor

The information contained herein is the confidential property of BioSpectra. The recipient is responsible for its safe-keeping and the prevention of unauthorized appropriation, use, disclosure and copying.

	,			